Description of HbA1c Levels in Fatty Liver Disease Patients in a West Jakarta Private Hospital in 2018-2019
Article Sidebar
Main Article Content
Abstract
Fatty liver disease is a chronic disease that is very often found in the community and is often called "silent" liver disease because there are no specific symptoms in patients. The incidence of fatty liver disease in Indonesia is quite high by 30 percent and this disease can develop into liver cirrhosis. The high incidence of fatty liver disease can be caused by various factors such as obesity, dyslipidemia, hypertension, unhealthy lifestyles and insulin resistance. Insulin resistance can be characterized by an increase in HbA1c levels in the blood. This study aims to determine the description of HbA1c levels in patients with fatty liver disease. This research is an observational descriptive study using a cross-sectional approach by using medical record data of fatty liver disease patients who have been on radiologic examination and doing HbA1c examination. Fatty liver disease affects more male sex groups by 55.4 percent, with the most age range at 51-60 years by 34.9 percent. Diabetes HbA1c levels (59%) are more than prediabetes (25.3%) and normal HbA1c levels (15.7%). Abnormal HbA1c levels (prediabetes and diabetes) were found to be higher in men (47 % vs 47,3%). The most accompanying diseases in patients with fatty liver disease are diabetes mellitus (51.8%), hypertension (33.7%), dyslipidemia (26.5%), dyspepsia (28.9%), and hyperuricemia (15.7%). Fatty liver disease patients were also found to have metabolic syndrome by 54.2% which was dominated by female sex by 53.3% with 91.1% having 3 components of metabolic syndrome and 8.9% having 4 components of metabolic syndrome
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
C. O. M. JASIRWAN, A. MURADI, I. HASAN, M. SIMADIBRATA, en I. RINALDI, “Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease”, Biosci. Microbiota, Food Heal., vol 40, no 1, bll 50–58, 2021, doi: 10.12938/bmfh.2020-046.
P. WU, R. HUANG, Y.-L. XIONG, en C. WU, “Protective effects of curcumin against liver fibrosis through modulating DNA methylation”, Chin. J. Nat. Med., vol 14, no 4, bll 255–264, Apr 2016, doi: 10.1016/S1875-5364(16)30025-5.
F. N. Akbar, S. R. Choirida, A. Z. Muttaqin, F. Ekayanti, H. Nisa, en H. Hendarto, “Telemedicine as an Option for Monitoring Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Patients Facing the COVID-19 Pandemic: A Systematic Review and Meta-Analysis”, J. Pers. Med., vol 14, no 3, bl 281, 2024.
C. O. M. Jasirwan et al., “Correlation of Gut Firmicutes/Bacteroidetes Ratio with Fibrosis and Steatosis in Patients with Non-alcoholic Fatty Liver Disease”, 2020, doi: https://doi.org/10.21203/rs.3.rs-23643/v1.
B. A. Riccardo et al., “The role of curcumin in liver diseases”, Arch Med Sci, 2017.
L. Legiawati, K. Bramono, W. Indriatmi, E. Yunir, en A. I. Pratama, “Type 2 diabetes mellitus with early dry skin disorder: a comparison study between primary and tertiary care in Indonesia”, Curr. Diabetes Rev., vol 18, no 2, bll 89–97, 2022.
F. L. Safitri en W. N. Hasmar, “Evaluation Of The Accuracy Of Antididiabetic Agents In Patients With Diabetes Mellitus Type Ii In The Inpatient Installation Of One Of The Private Area Hospitals East Bekasi 2020”.
B. Li, C. Zhang, en Y.-T. Zhan, “Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis”, Can. J. Gastroenterol. Hepatol., vol 2018, bll 1–8, Jul 2018, doi: 10.1155/2018/2784537.
J. J. Setiawan, P. Hendra, en N. A. P. Susanto, “High Frequency of CYP2A6* 4, CYP2A6* 7, and CYP2A6* 9 Alleles Detected Among Patients with Type 2 Diabetic: Genetic Study in”, Res. Artic. High Freq. CYP2A6* 4, CYP2A6* 7, CYP2A6* 9 Alleles Detect. Among Patients with Type 2 Diabet. Genet. Study Priv. Hosp. Yogyakarta, vol 19, no 2, bl 53, 2022.
P. B. Liman et al., “Dietary and Plasma Carboxymethyl Lysine and Tumor Necrosis Factor-α as Mediators of Body Mass Index and Waist Circumference among Women in Indonesia”, Nutrients, vol 11, no 12, bl 3057, Des 2019, doi: 10.3390/nu11123057.
A. Jiménez Herrerías, “Evolución clínica valorada mediante rigidez hepática tras tratamiento con antivirales de acción directa en pacientes VHC”, 2022.
M. Nouri‐Vaskeh, A. Malek Mahdavi, H. Afshan, L. Alizadeh, en M. Zarei, “Effect of curcumin supplementation on disease severity in patients with liver cirrhosis: A randomized controlled trial”, Phyther. Res., vol 34, no 6, bll 1446–1454, Jun 2020, doi: 10.1002/ptr.6620.
J. H. Yoo et al., “Mean and visit‐to‐visit variability of glycated hemoglobin, and the risk of non‐alcoholic fatty liver disease”, J. Diabetes Investig., vol 12, no 7, bll 1252–1262, 2021.
F. F. Dieny, S. Rose, en A. F. A. Tsani, “Body Mass Index is The Most Associated Anthropometry Indicators of Obesity with Insulin Resistance in Female College Students”, J. Gizi Indones. (The Indones. J. Nutr., vol 11, no 1, bll 66–76, 2022.
R. S. Siregar, R. A. Hadiguna, I. Kamil, N. Nazir, en N. Nofialdi, “Ginger (Zingiber officinale R.) as a Potent Medicinal Plant for the Prevention and Treatment of Diabetes Mellitus: A Review.”, Trop. J. Nat. Prod. Res., vol 6, no 4, 2022.
C. Li et al., “Increased risks of different grades of non‐alcoholic fatty liver disease in prediabetic subjects with impaired fasting glucose and glucose tolerance, including the isolated glycosylated hemoglobin levels of 5.7–6.4% in a Chinese population”, J. Diabetes Investig., vol 11, no 5, bll 1336–1343, 2020.
R. M. Javier et al., “Systematic Review: Risk Factors of Uterine Gangrene Disease in Cervical Cancer With Type 2 Diabetes Mellitus”, 2023, doi: https://doi.org/10.21203/rs.3.rs-3311553/v1.
A. F. M. Z. Zein, K. Safitri, T. O. Per-Matasari, U. Hasanah, C. S. Sulistiyana, en T. M. Pratamawati, “The proportion of gastroesophageal reflux disease in patients with type 2 diabetes mellitus and dyspepsia”, in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, vol 34, bl 234.
D. A. Rachmawati, A. Sa’adi, B. Utomo, en A. Tunjungseto, “Relationship between angiopoietin-like-protein-2 levels and anti-mullerian hormone levels in polycystic ovary syndrome of reproductive age”, Bali Med. J., vol 12, no 1, bll 861–865, 2023, [Online]. Available at: http://repository.unair.ac.id/id/eprint/127982.
S. Saadati et al., “The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease”, Eur. J. Clin. Nutr., vol 73, no 3, bll 441–449, Mrt 2019, doi: 10.1038/s41430-018-0382-9.
R. Rajalakshmi, V. Prathiba, R. Raman, P. Ruamviboonsuk, R. Pradeepa, en V. Mohan, “The Burden of Non-communicable Diseases and Diabetic Retinopathy”, South-East Asia Eye Heal. Syst. Pract. Challenges, bll 197–228, 2021.
M. Nouri-Vaskeh, H. Afshan, A. M. Mahdavi, L. Alizadeh, X. Fan, en M. Zarei, “Curcumin ameliorates health-related quality of life in patients with liver cirrhosis: A randomized, double-blind placebo-controlled trial”, Complement. Ther. Med., vol 49, bl 102351, 2020, doi: https://doi.org/10.1016/j.ctim.2020.102351.
Lady Lady Aqnes Kurniawati, M. Muhammad Ilham Aldika Akbar, B. Budi Utomo, en A. Aditiawarman, “Risk Factor of Preeclampsia in a Secondary Indonesian Hospital: A Case-Control Study”, Indian J. Forensic Med. Toxicol., vol 15, no 3, bll 3474–3482, 2021, [Online]. Available at: http://repository.unair.ac.id/id/eprint/121010.
T. Shibuya et al., “Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non‐alcoholic fatty liver disease: a prospective randomized controlled pilot study”, Diabetes, Obes. Metab., vol 20, no 2, bll 438–442, 2018.
A. Alexopoulos et al., “Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease”, Hepatology, vol 74, no 3, bll 1220–1233, 2021.
A. A. A. Acosta et al., “Impact of Bariatric Surgery on Cardiovascular Diseases: Integrative Review”, Asian J. Res. Nurs. Heal., vol 6, no 2, bll 42–57, 2023, [Online]. Available at: http://journal.article2publish.com/id/eprint/1578.
M. Masroor en Z. Haque, “HbA1C as a Biomarker of Non-alcoholic Fatty Liver Disease: Comparison with Anthropometric Parameters”, J. Clin. Transl. Hepatol., vol 000, no 000, bll 1–7, Mrt 2021, doi: 10.14218/JCTH.2019.00046.
T. J. Bivalacqua et al., “The Diagnosis and Management of Priapism: an AUA/SMSNA Guideline (2022)”, 2022.
K. Tanaka et al., “Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non‐alcoholic fatty liver disease”, Hepatol. Res., vol 49, no 3, bll 296–303, 2019.
R. Zupo et al., “Non Alcoholic Fatty Liver Disease Is Positively Associated with Increased Glycated Haemoglobin Levels in Subjects without Diabetes”, J. Clin. Med., vol 10, no 8, bl 1695, Apr 2021, doi: 10.3390/jcm10081695.
B. I. Afolabi, B. O. Ibitoye, R. T. Ikem, A. D. Omisore, B. M. Idowu, en D. O. Soyoye, “The Relationship Between Glycaemic Control and Non-Alcoholic Fatty Liver Disease in Nigerian Type 2 Diabetic Patients”, J. Natl. Med. Assoc., vol 110, no 3, bll 256–264, Jun 2018, doi: 10.1016/j.jnma.2017.06.001.